A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee.

@article{Spierings2013API,
  title={A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee.},
  author={Egilius L H Spierings and James Fidelholtz and Gernot Wolfram and Michael D. Smith and M. T. Brown and Christine R. West},
  journal={Pain},
  year={2013},
  volume={154 9},
  pages={
          1603-12
        }
}
Tanezumab is a humanized monoclonal antinerve growth factor antibody in development for treatment of chronic pain. In a phase III, placebo- and active-controlled study, we investigated the efficacy and safety of tanezumab for osteoarthritis (OA) hip or knee pain. Patients (N=610) received up to 2 doses of intravenous tanezumab (5 or 10mg in 8-week intervals), controlled-release oral oxycodone (10 to 40 mg every 12 hours), or placebo. The primary endpoint was mean change from baseline to week 8… CONTINUE READING